Le Lézard
Classified in: Health
Subject: FDA

Acella Pharmaceuticals, LLC, announces approval of generic to Vituz® Oral Solution

ATLANTA, July 27, 2017 /PRNewswire/ -- Acella Pharmaceuticals, LLC, a leading U.S. developer of specialty pharmaceuticals across several therapeutic categories, recently announced the Food and Drug Administration's approval of the Company's abbreviated new drug application (ANDA) for a Hydrocodone Bitartrate and Chlorpheniramine Maleate Oral Solution 5 mg/4 mg per 5 mL as a bioequivalent product to VITUZ® Oral Solution. This approval continues Acella Pharmaceuticals' diverse portfolio of products and the commitment to provide effective and affordable health care solutions for its broad and growing base of customers.

Acella Pharmaceuticals, LLC

This combination medicine is indicated for relief of cough and symptoms associated with upper respiratory allergies or a common cold in adults 18 years of age and older. The incidence of the common cold exceeds one billion cases in the United States each year. A majority of the population is likely to have more colds than any other type of illness. Colds can occur at any time of the year, but they are most common in the winter or rainy seasons. 1-3

"Acella continues to actualize new product launch opportunities that align with our strategic mission to provide optimal healthcare support for the medical community and their patient population," said Harold A. Deas, Jr., CEO for Acella Pharmaceuticals.

"Access to affordable and effective solutions for common illnesses is critical in our current healthcare environment," said Allen Fields, Acella's Senior VP, Clinical and Regulatory Affairs, Head of Research and Development. "Our team at Acella will continue to focus on product opportunities to positively impact the greatest healthcare needs in our society."

About Acella Pharmaceuticals, LLC

Acella develops, markets, sells and distributes a broad portfolio of non-branded pharmaceutical and other products in the areas of Dermatology, Women's Health, Pediatrics and other applications.  Acella specializes in identifying and bringing to market quality, affordable products to customers and patients.  For additional information please contact Acella at 678-325-5189, or visit www.acellapharma.com.

An Abbreviated New Drug Application (ANDA) contains data which, when submitted to FDA's Center for Drug Evaluation and Research, Office of Generic Drugs, provides for the review and ultimate approval of a generic drug product. Once approved, an applicant may manufacture and market the generic drug product to provide a safe, effective, low-cost alternative to the American public.

A generic drug product is one that is comparable to an innovator drug product in dosage form, strength, route of administration, quality, performance characteristics and intended use.  All approved products, both innovator and generic, are listed in FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).

1 Turner RB. The common cold. In: Goldman L, Schafer AI, eds. Goldman's Cecil Medicine. 24th ed. Philadelphia, PA: Saunders Elsevier; 2011:chap 369.
2 Fashner J, Ericson K, Werner S. Treatment of the common cold in children and adults. Am Fam Physician. 2012;86(2):153-159.
3 Singh M, Das RR. Zinc for the common cold. Cochrane Database of Systematic Reviews. 2011, Issue 2. Art. No.: CD001364.

SOURCE Acella Pharmaceuticals, LLC

These press releases may also interest you

at 09:01
While the ability of grape seed extract's oligomeric proanthocyanidins (OPC) to prevent tumors has been previously demonstrated, the underlying mechanisms have not been fully explored. A recent study, published in the journal Scientific Reports, has...

at 09:00
Processa Pharmaceuticals, Inc. announced today that, as agreed in the asset purchase of Promet Therapeutics, LLC, Processa has been assigned the license for CTP-499 upon Promet's exercising of the exclusive option to license in CTP-499 from Concert...

at 09:00
CVS Health today announced two initiatives in New Hampshire to combat opioid abuse.  The company has installed safe medication disposal units inside two CVS Pharmacy locations in New Hampshire to help facilitate proper and timely disposal of opioids...

at 09:00
AbbVie , a research and development-based global biopharmaceutical company, and the International Myeloma Foundation (IMF) today announced they have entered into a collaboration to conduct a landmark retrospective chart review study to better...

at 09:00
FN Media Group Presents USA News Group News Commentary  USA News Group - As evidence to the shift in public perception of marijuana use, the Province of Ontario has announced plans to legalize Cannabis lounges once the country's Cannabis Act is...

at 09:00
Collagen Matrix, Inc., a leader in regenerative medicine and a global manufacturer of collagen and mineral based medical devices, announced today the appointment of Gregory Pomrink as Vice President, Research and Development to further leverage its...

News published on 27 july 2017 at 09:10 and distributed by: